Lv1
40 积分 2024-06-28 加入
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
4个月前
已完结
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
5个月前
已完结
Retrospective analysis of serum free light chain reference intervals and risk for monoclonal gammopathy suggests different limits than those in international guidelines
9个月前
已完结
皖公网安备34019202002308
